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Rosacea is a common chronic skin condition that displays 
a broad diversity of clinical manifestations. Although the 
pathophysiological mechanisms of the 4 subtypes are not 
completely elucidated, the key elements often present are 
augmented immune responses of the innate and adaptive 
immune system, and neurovascular dysregulation. The 
most common primary feature of all cutaneous sub types 
of rosacea is transient or persistent facial ery thema. Pe-
rilesional erythema of papules or pustules is based on 
the sustained vasodilation and plasma extravasation 
induced by the inflammatory infiltrates. In contrast, 
transient erythema has rapid kinetics induced by trigger 
factors independent of papules or pustules. Amongst the 
current treatments for facial erythema of rosacea, only 
the selective α2-adrenergic receptor agonist brimonidine 
0.33% topical gel (Mirvaso®) is approved. This review 
aims to discuss the potential causes, different pathophy-
siologies and current treatment options to address the 
unmet medical needs of patients with facial erythema 
of rosacea. Key words: rosacea; erythema; brimonidine; 
patho physiology; vasculature; treatment.
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Rosacea is a common chronic facial skin disease with 
female predominance that affects millions of patients 
worldwide, mostly individuals with fair skin (Fitzpatrick 
phenotypes I–II) and the northwest European population 
(1–3). Rosacea is diagnosed when one or more of the fol-
lowing primary features are present: flushing (transient 
erythema); persistent (non-transient) erythema in certain 
facial areas; papules and pustules; and telangiectasia (2, 
4). Secondary features are often present alongside the 
primary symptoms, but can also appear independently 
and include burning or stinging, plaques, dry appearance, 
oedema, ocular involvement (e.g. blepharitis, “dry eyes”, 
photosensitivity, recurrent hordeolum), peripheral loca-
tion (e.g. scalp and ears) and phymatous changes (4, 5). 
To aid the different dominant features and for impro-
ved diagnosis, the most common patterns of signs and 
symptoms of rosacea have been designated as 4 different 
subtypes, erythematotelangiectatic (ETR), papulopustu-
lar (PPR), phymatous (PhR) and ocular (OR) (3), with 
ETR and PPR being the two most common subtypes (6).
CORRELATIONS BETWEEN CLINICAL 
FEATURES AND VASCULAR CHANGES
As a broad diversity of clinical manifestations are as-
sociated with rosacea, a variety of pathophysiological 
mechanisms have been linked with the different clinical 
presentations; none of these mechanisms have been 
completely elucidated. One of the reasons for this is 
that all 4 subtypes have never been studied in parallel. 
Moreover, in PPR, biopsies have mostly been taken 
from papules or pustules, and have not been compared 
with erythematous areas in PPR (1, 7). It is thought 
that although no single mechanism is dominant in all 
cases of rosacea, each individual mechanism has a 
varying presence in individual cases and may corre-
late with the different clinical features (8). Again, an 
experimental basis for this hypothesis by comparison 
of the different subtypes does not exist. In addition to 
these pathophysiological aspects, rosacea also remains 
an under-diagnosed and under-treated skin condition 
(2). In particular, the treatment of facial erythema of 
rosacea is a common clinical challenge.
It is not yet clear if rosacea subtypes develop in a 
progressive serial fashion, or if the subtypes occur as dis-
crete variants (1, 9). However, patients often report that 
rosacea symptoms start with transient flushing that later 
gives way to a persistent erythema. Facial erythema, the 
most common primary feature of all subtypes of rosacea, 
has been described as a mandatory diagnostic feature and 
is thus the predominant mark of patients with rosacea, 
especially in the ETR and PPR subtypes, but it can also be 
present in PhR and OR (2, 4, 6, 10). Precise data for this 
observation, however, are still lacking. Facial erythema 
is usually diffuse in nature, generally persists despite 
resolution of inflammatory lesions and predominantly 
occurs in a central position on the face (8).
Vascular changes in susceptible individuals are 
thought to be triggered by certain environmental or 
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lifestyle factors (including ultraviolet [UV] exposure, 
temperature changes, exercise, spicy food and alcohol 
consumption [of note, certain alcoholic beverages more 
than others]) (7, 11). Whether transient and persistent 
types of erythema possess a different pathophysiology is 
still unknown. Moreover, the quantity and quality of the 
various trigger factors that induce erythema in a single 
patient vary. Flushing shares many clinical and histolo-
gical characteristics as well as kinetic development of 
capsaicin-induced neurogenic inflammation (12–14), 
comprising of sustained vasodilation, oedema of the 
superficial dermis and leukocyte infiltration (15). In ad-
dition to erythema, extensive telangiectasias throughout 
the superficial and middle dermis are a main histological 
feature of ETR, but may also occur in other subtypes. 
However, the presence of enlarged, dilated capillaries, 
arterioles and venules in the superficial dermis, often 
of unusual shapes, is particularly important in ETR (7). 
Signs of blood vessel angiogenesis only occur in the PhR 
subtype (16). In contrast to flushing, a different pathome-
chanism appears to underlie blushing. This review aims 
to discuss the complexities of facial erythema, covering 
the potential causes, pathophysiology, current treatments 
and unmet needs in patients with this condition.
AETIOLOGY
The aetiology and pathophysiology of rosacea are not 
completely understood, and the clinical course likely 
varies from patient to patient (17). Due to the increased 
prevalence of rosacea in northern Europeans, a genetic 
predisposition is suspected; however, the genes in-
volved are yet to be confirmed. Patients with rosacea 
have a greater than 4-fold increased chance of having 
a family member with rosacea compared with the ge-
neral population, and two single-nucleotide polymor-
phisms (SNPs) have recently been identified as being 
associated with rosacea in a genome-wide association 
study, supporting a genetic predisposition (1, 18). One 
of these SNPs is intergenic but located in proximity 
to a gene involved in histocompatibility and immune 
response (human leukocyte antigen [HLA] class II his-
tocompatibility antigen, DR alpha chain [HLA-DRA]), 
which is consistent with the inflammatory nature of the 
disease. However, the rosacea subtype of these patients 
was not confirmed and it is therefore unknown whether 
these SNPs are associated with the erythema of rosacea. 
Genetic analyses have also identified polymorphisms 
in the glutathione S-transferase genes, responsible for 
cellular defence against reactive oxygen species (ROS) 
damage (19). These polymorphisms; leading to exces-
sive ROS formation induced by UV light, may be a 
genetic risk factor in the development of rosacea (19). 
Gene array and real-time polymerase chain reaction 
(PCR) analyses indicate a defined gene profile for each 
of the different rosacea subtypes (with some overlap 
between ETR, PPR and PhR), which also differs from 
healthy skin (1, 8, 14). Proposed contributory factors to 
the development of rosacea include: abnormal vascular 
reactivity; dysregulation of the innate immune system; 
increased susceptibility of sensory nerves to tempera-
ture changes or other trigger factors such as spicy food, 
ethanol, exercising or climatic exposures (including UV 
radiation); high ROS levels; increased serine protease 
or matrix metalloproteinase (MMP) activity; Demodex 
overgrowth; or small intestinal bacterial overgrowth 
(SIBO) and pilosebaceous unit abnormalities; with 
variable proof by evidence-based data (2, 9, 20–23). 
Triggers for flushing events and aggravation of 
rosacea include a wide variety of physical, chemical, 
psychological and emotional factors including tempe-
rature changes (heat, noxious cold), UV irradiation, 
ingredients of spicy food (e.g. mustard oil or capsaicin), 
certain alcoholic beverages, increased body tempe-
rature (exercising), certain cosmetic formulations or 
emotional stress (24, 25). In this context, the transient 
receptor potential (TRP) family of receptors should be 
mentioned. They are a diverse group of non-selective 
cation channels activated by these various rosacea trig-
ger factors that can subsequently mediate and maintain 
some of the symptoms of rosacea (flushing as part of 
acute neurogenic inflammation) (Fig. 1) (13, 14). In ad-
dition, lipid metabolites (e.g. sphingosine-1-phosphate 
[S1P]), organic alcohols (ethanol) and their metabolites 
(acetaldehyde) or hormones (e.g. neurohormones) can 
modulate vascular changes during inflammatory proces-
ses and may thus play a role in rosacea (1, 26–28). The 
short half-life of S1P favours a role of this mediator for 
rapid modulation of vascular tone. In general, however, 
neurogenic inflammation optimally mimics the rapid 
onset and kinetics of a flushing incident, and is induced 
by sensory nerve activation (15, 16, 29). The aetiology 
of other, rarer, variants such as rosacea conglobata or ful-
minans (also known as pyoderma faciale) are also poorly 
understood. The latter only affects young women, often 
during or after pregnancy, indicating a role of hormonal 
dysregulation in this rosacea variant (30). The fact that 
ETR is not primarily associated with adolescence or 
menopause argues against a significant contribution of 
hormonal factors in the 4 rosacea subtypes.
PATHOPHYSIOLOGY
Although rosacea has been recognised for thousands of 
years, its pathophysiology is not well defined and the 
role of the so-called “trigger factors” in the causation 
or exacerbation of rosacea is yet to be fully elucidated 
(24). Rosacea shows huge variations in clinical manifes-
tations and as such probably encompasses a wide range 
of pathophysiological mechanisms that are not fully 
elucidated (Fig. S11) (7). The key pathophysiological 
elements that are often present are augmented immune 
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activation and response, and neurovascular dysregula-
tion (6, 7). However, a critical problem is that early 
ETR (commonly-termed ‘pre-rosacea’ or ‘early-onset 
rosacea’), which manifests as transient flushing without 
any other rosacea signs or symptoms and is dependent 
on rosacea trigger factors, has not been thoroughly 
investigated. So far, researchers have found a marked 
upregulation of genes involved in vasoregulation and 
neurogenic inflammation in all subtypes of rosacea (16). 
However, the correlation with dysregulated protein 
levels in the pathophysiology of rosacea remains to be 
studied; thus, the cause or causes leading to transient 
flushing and subsequent persistent erythema are still 
poorly understood in humans. The most promising preli-
minary evidence for a pathophysiological impact for the 
induction of erythema and vasodilation demonstrates 
an involvement of antimicrobial peptides and proteases 
(31), neuropeptides (9) or TRP ion channels (14).
Various microbes including bacteria or mites have 
been implicated in the pathophysiology of rosacea. 
A role of Helicobacter pylori could not be verified in 
various studies (32, 33), but a role of a dysregulated 
microbiome in patients with SIBO might be responsible 
for rosacea in a certain subset of patients (22). 
Demodex folliculorum or bacteria digested within 
Demodex mites have been implicated in the pathophy-
siology of rosacea and are thought to trigger the innate 
immune responses rather than be a mandatory component 
(23, 26). However, gene array studies and histological 
data do not support an important role for known microbial 
agents in the early phase of rosacea (ETR) (1, 17, 34). As 
Fig. 1. Potential mechanisms of transient receptor potential vanilloid 1 (TRPV1)- and ankyrin 1 (TRPA1)-mediated inflammatory responses in rosacea. 
TRPV1 and TRPA1 are non-selective cation (calcium) channels that are activated by rosacea trigger factors and are significantly upregulated in rosacea 
human tissue. TRPV1 and/or TRPA1 are activated by spices, temperature changes or alcohol. Both can be expressed by neuronal or non-neuronal tissues. 
Subsequent depolarisation after calcium influx induces release of neuropeptides, including for example substance P (SP), pituitary adenylate cyclase-
activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP). Neuropeptide action on blood vessels causes vasodilation (responsible 
for erythema and flushing) and plasma extravasation (oedema). Flushing is usually transient in healthy individuals but may be sustained in patients with 
rosacea. Neuropeptide response on T cells, mast cells and macrophages results in activation or aggravation of the inflammatory response by release 
of cytokines, lipids, proteases or prostanoids. Macrophages release proteases upon stimulation by cytokines. Smooth muscle cells relax in response to 
neuropeptides and/or nitric oxide (NO). RBC: red blood cell; ROS: reactive oxygen species. (Modified from Steinhoff et al. (9), Aubdool et al. (13), Sulk 
et al. (14), Sulk et al. (16), Schauber et al. (99)).
1http://www.medicaljournals.se/acta/content/?doi=10.2340/00015555-2335
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with SIBO and chemical trigger factors, it is possible that 
different trigger factors in different subgroups lead to the 
same clinical manifestions of rosacea, similar to what is 
observed for IgE+ and IgE– atopic dermatitis. In future, 
thorough studies must include all subtypes of rosacea. 
Of note, no evidence-based studies exist regarding the 
incidence of trigger factors including Demodex or bac-
teria such as Bacillus oleronius in early ETR.
Augmented immune response
In patients with ETR, there is a marked upregulation 
of proinflammatory and vasoregulatory genes (8). The 
inflammatory infiltrate, which is present in all 4 sub-
types, is still poorly characterised. In ETR, a lympho-
monocytic infiltrate consisting of predominantly CD3+ 
T cells (70–80%), 10–20% CD20+ B cells, and a few 
histiocytes, has been described (7). However, a more 
precise immunohistochemical characterisation of all 
subtypes of rosacea would be desirable. Comparing 
ETR, PPR and PhR, an increase in mast cell numbers 
has been described in all of these subtypes (7, 16). 
An increased infiltrate of dendritic cells has been 
described for rosacea (35). Our data indicate that in-
creased numbers of CD4+ type 1 helper T cells (Th1), 
macrophages and mast cells can be found in these 3 
subtypes, whereas B-cell expression is variable, and 
possibly related to microbial involvement in certain 
patients (36). Whether these changes are found in 
patients with an increased density of Demodex mites 
or bacteria such as B. oleronius, which may trigger an 
inflammatory response, needs to be clarified (37). In 
ETR, it is thought that there is an early involvement of 
the innate immune system and, to a lesser extent, the 
adaptive immune system (8). However, upregulation of 
both adaptive and innate immune response genes has 
been demonstrated in patients with ETR, PPR and PhR 
(1, 8); thus, a contribution of the adaptive immune sys-
tem is likely, although it is still poorly understood (1). 
The mixed inflammatory infiltrate associated with 
PPR is characterised by Th1 cells, macrophages and 
mast cells. Plasma cells are only occasionally seen and 
neutrophils are limited to pustules (7, 36). When compa-
ring samples from healthy skin with those from patients 
with PPR, it has been noted that there is an increase in 
levels of bioactive cathelicidin antimicrobial peptides 
(in particular LL-37) and the cathelicidin-processing 
serine protease kallikrein-5 (31). LL-37 is a potent mo-
dulator of the innate immune response and modulates 
the pro-inflammatory UV response in rosacea (21, 38). 
Accordingly, gene expression of cathelicidin and kal-
likrein-5, and activity of serine proteases was inhibited 
during treatment of rosacea with azelaic acid 15% gel 
(39). Toll-like receptor 2 (TLR2; known to increase 
kallikrein-5 expression) is also elevated in PPR (40). 
TLR2 activates the nucleotide-binding oligomerisa-
tion domain (NOD)-like receptor family, pyrin domain 
containing 3 (NLRP3) inflammasome, thus initiating 
caspase-1 activation, release of the pro-inflammatory 
cytokine IL-1β and subsequent downstream inflamma-
tory responses (41). TLRs are expressed on sensory neu-
rons and may be responsible for a link between nerve 
stimulation and augmented innate immunity (42–44).
This pathway of increased cathelicidin expression and 
increased production of LL-37 peptides has been linked 
to the endoplasmic reticulum (ER) stress response. ER 
stress has been suggested as a key factor in the patho-
genesis of rosacea, and in fact, all clinical rosacea 
trigger factors induce ER stress (45). TLR2 expression 
and activity is increased in response to ER stress (46), 
demonstrating its role in augmented innate immunity and 
also providing a link to enhanced nociception. ER stress 
stimulates cathelicidin production and the synthesis of 
LL-37 in keratinocytes and epithelial cells via a novel 
nuclear factor-kappa B (NFκB) pathway (via downstream 
activation of the cathelicidin gene promoter) (47). The 
lipid mediator S1P is upregulated in ER stress and is 
responsible for this increase in cathelicidin (48). This 
increased activity associated with cathelicidin expression 
and metabolism promotes chemoattraction of inflamma-
tory cells and angiogenesis, and may alter the expression 
of certain components of the extracellular matrix (31, 49). 
LL-37 works in synergy with IL-1β to modulate the 
immune response (50). The NLRP3 inflammasome is 
responsible for the production of IL-1β; therefore, ER 
stress leading to TLR2 upregulation (and production of 
LL-37) is directly connected to NLRP3 inflammasome 
activation and inflammation in the skin (41). The atte-
nuation of ER stress-mediated TLR2 signalling by anti-
rosacea treatment provides evidence for the role of ER 
stress in the augmented immune response of rosacea (45). 
Gene array and real-time PCR analysis of healthy 
skin compared with ETR, PPR and PhR indicate that 
a number of different factors are involved in the dys-
regulation of the inflammatory response in rosacea, 
including cytokines, chemokines, metalloproteinases, 
proteases, ROS, alcohol and lipid metabolites (1). 
However, a systematic genetic profiling of the inflam-
matory mediators involved in the different subtypes of 
rosacea is still lacking (36). When available, it will be 
critical to correlate these mRNA studies with quanti-
tative immunohistochemical and protein data in order 
to understand the complex phases of inflammatory 
responses in the different subtypes of rosacea.
Another potentially important element in the patho-
physiology of rosacea is an impaired stratum corneum 
barrier function (8). Increased stratum corneum permea-
bility is probably structurally and functionally linked to 
an aggravated innate immune response in patients with 
rosacea. It is possible that the innate immune system is 
activated as a homeostatic counter-regulatory response 
to an impaired stratum corneum barrier, resulting in 
increased trans-epidermal water loss and an increase 
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in mRNA expression levels, as well as secretion of 
cathelicidin peptides (LL-37) (34). Future experiments 
will have to verify the exact role of the innate immune 
system in all subtypes of rosacea.
VASCULAR CHANGES
Clinically, different vascular changes have to be dif-
ferentiated in rosacea patients: a) transient flushing that 
lasts for minutes to hours; b) persistent erythema that 
lasts for days to weeks; c) perilesional erythema around 
papules or pustules. A fourth vascular reaction that can 
occur concurrently in rosacea patients and often leads 
to confusion is “blushing”. Blushing is a more pinkish, 
lighter erythema that is not predominantly located in the 
facial T-zone (central face), but more homogeneously 
distributed in the central face and peripheral cheeks, as 
well as behind the ears, which is not present in flushing. 
Blushing is mediated by the sympathetic nervous system 
as a response to emotional or stressful events (51). We be-
lieve that the pathophysiological mechanism of blushing 
is the same in rosacea patients as in the healthy popula-
tion and, importantly, that it is different from the flushing 
mechanism. Blushing is transient and not associated with 
inflammation (51), but its occurrence can be a confoun-
ding factor in rosacea. In contrast, flushing triggered 
by stimulation of the sensory nerves through release 
of neuropeptides may also result in acute inflammation 
(neurogenic inflammation). The fact that patients with 
ETR already have a marked mast cell infiltrate and sig-
nificant local increase of inflammatory neuromediators 
and cytokines (16, 52) indicates that flushing is an acute 
inflammatory process induced by sensory nerves, known 
since the early works of Jancsó et al. (53) (reviewed by 
Roosterman et al. (15)). Therefore, it must be assumed 
that a different pathomechanism underlies each vascular 
mechanism (1). This hypothesis is also supported by a 
recent human study in which laser Doppler was used to 
detect blood flow after iontophoresis of acetylcholine. 
The results indicate that an axon reflex mechanism is 
responsible for enhanced flushing in patients with the 
most severe rosacea symptoms (54). 
Vasoregulatory mediators
The critical mediators that induce sustained flushing in 
rosacea patients may be potent vasoregulatory neuro-
peptides such as pituitary adenylate cyclase-activating 
polypeptide (PACAP), vasoactive intestinal peptide 
(VIP) or calcitonin gene-related peptide (CGRP), as 
well as lipid or alcohol metabolites that can also in-
duce prolonged vasodilation (1, 9, 13, 15, 27, 55, 56). 
Substance P (SP) may also contribute to the oedema, as 
seen in all 3 subtypes of rosacea at the microscopic level 
(16, 57). Other potent vasodilators of skin blood vessels 
are ROS and proteases (13, 31). All 3 skin-subtypes of 
rosacea demonstrate similar histopathological changes 
with enlarged, dilated arterioles, capillaries and venules 
in the upper dermis (7, 16), postcapillary oedema and 
transmigration of leukocytes (predominantly T cells 
and monocytes) (7–9). MMPs that are abundantly 
enhanced at the mRNA level (up to 300-fold) in all 
3 skin-subtypes of rosacea, especially MMP-12, -1 
and -9 may critically contribute to tissue destruction 
and development of telangiectasias (9, 16). mRNA 
levels of markers for angiogenesis or lymphatic vessel 
regulation such as vascular endothelial growth factor 
A (VEGFA), CD31, podoplanin or lymphatics (D2-40) 
are also increased in rosacea patients (8). However, 
these mRNA levels do not correlate positively with 
morphometric immunohistochemistry data that indicate 
marked vasodilation in ETR and PPR without evidence 
of angiogenesis (although it is present in PhR) (16). 
Whether this argues for an existing subtype progression 
from ETR/PPR to PhR through chronic inflammatory 
processes that result in the fibrotic changes in PhR will 
have to be assessed in the future. Despite all structural 
changes, functional vascular responsiveness in rosacea 
patients remains intact, with aggravated and sustained 
vasodilation in response to the above-mentioned trigger 
factors still operational in ETR, PPR and PhR (1, 8, 14).
TRP channels
One of the hallmarks of rosacea is increased vasodi-
lation in response to various trigger factors (8). As 
previously described, many of the trigger factors for 
rosacea (particularly spicy food, heat, noxious cold, 
exercising and alcohol) also activate ion channels 
such as members of the TRP receptor family, including 
TRPV1 and TRPA1, which are located on nociceptive 
nerve endings and are involved in prolonged vasodila-
tion and neurogenic inflammation (1, 13, 14, 58). Their 
activation by these trigger factors may lead to transient 
flushing even in healthy individuals. Patients with rosa-
cea, however, may experience a sustained activation of 
TRP channels on nociceptors, resulting in flushing and 
neurogenic inflammation with leukocyte infiltration. It 
has been noted that patients with rosacea have a high 
density of TRPV1-positive nerve fibres and increased 
levels of TRPV1 mRNA expression (1). As TRPV1 
is expressed by sensory nerves, endothelial cells (as 
shown in mice) and keratinocytes (possibly associated 
with skin inflammatory responses), the primary source 
for TRPV1 dysfunction may be the sensory nerve or 
the endothelium itself (1, 59, 60). Future studies in 
humans are required to clarify this important question.
Pathophysiological mechanisms of persistent erythema
Taken together, in addition to the transient “flushing” 
of rosacea patients and the transient “blushing” in 
healthy humans due to sympathetic activation, there 
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are 3 different types of persistent erythema that have 
to be differentiated because of different underlying 
regulatory mechanisms: i) persistent facial erythema 
of rosacea patients; ii) perilesional erythema around 
papules and pustules in rosacea band also in acne or 
other diseases (i.e. not rosacea-specific) and iii) other 
“erythematous” inflammatory origins that can some-
times coincide with rosacea (2, 6). Examination of the 
location of inflammation combined with knowledge of 
the patient’s history can often identify the latter as ecze-
matous (e.g. seborrhoeic dermatitis, atopic dermatitis, 
other eczemas or tinea). Perilesional erythema is solely 
associated with inflammatory lesions such as papules 
and pustules, and disappears in conjunction with the 
clearance of the inflammatory lesions (8). 
After the differentiation of the different variants, what 
exactly is the pathophysiology of persistent erythema? 
Although the details of this mechanism remain un-
known, persistent erythema appears to be unaffected by 
anti-inflammatory treatments with systemic or topical 
antibiotics, azelaic acid or sulphur and mostly outlasts 
the apparent resolution of inflammatory lesions (8). But 
does this mean that persistent erythema has no inflam-
matory component? Not necessarily, because we know 
that the inflammatory lympho-monocytic, mast-cell rich 
infiltrate of ETR patients needs a relatively long time to 
resolve, as compared with transient flushing, and also 
that the erythema diminishes in correlation with the 
reduction of the inflammatory infiltrate (61). 
Moreover, several mediators involved in inflam-
mation and innate immunity such as proteases and 
antimicrobial peptides contribute to rosacea. The cuta-
neous vasculature can become structurally altered due 
to continuous vasodilatory stimulation and secondary 
inflammatory responses, caused by mediators such as 
LL-37, VEGF and some MMPs (8). The mechanism 
by which LL-37 enhances the release of inflammatory 
mediators and promotes angiogenesis is through NLRP3 
inflammasome activation (21). IL-1β modifies angioge-
nesis by decreasing angiopoietin-1 mRNA expression 
(62) and LL-37 and IL-1β can work synergistically to 
enhance the angiogenic function of endothelial cells 
(21). The vicious circle of vascular and inflammatory 
changes causes a persistent dilation of blood and lym-
phatic vessels, neoangiogenesis, telangiectasia forma-
tion and dermal matrix degradation (8).
Neurogenic vasoregulation in erythema
Facial skin perfusion in humans is modulated by neuro-
nal (sympathetic, parasympathetic and nociceptive) and 
non-neuronal (local inflammatory) mechanisms (Fig. 
2). The sympathetic vascular innervation has a mainly 
thermoregulatory function with vasoconstriction being 
mediated by the release of noradrenaline and neuro-
peptide Y (63), aided by local vasoconstriction upon 
cooling by α2c-receptors (64) and counteracted by ac-
tivation of β2-adrenoceptors. In contrast, the mediators 
of active sympathetic vasodilation – important for heat 
dissipation and also for emotional blushing – are not 
yet identified (candidates include VIP, nitric oxide (63) 
and PACAP (55)). Cholinergic parasympathetic reflex 
vasodilation is induced by irritation in the eyes, mouth, 
nose (65) and also following strong gustatory stimuli 
(66). In addition, skin nociceptors being activated by 
local inflammatory mediators release vasodilatory neu-
ropeptides (CGRP and SP) in their innervation territory 
(“axon-reflex” effector). Skin perfusion in facial skin is 
more complex due to arteriole–venule anastomoses that 
are controlled by combined sympathetic and nociceptive 
innervation (67). If dilated, the arteriole–venule shunts 
Fig. 2. Mechanisms of facial skin perfusion. Facial skin perfusion is 
modulated by neuronal and non-neuronal mechanisms. Sympathetic 
vasoconstriction is mediated by noradrenaline and neuropeptide Y (NPY), 
whereas mediators of active sympathetic vasodilation are not completely 
clarified, but probably include pituitary adenylate cyclase-activating 
polypeptide (PACAP), vasoactive intestinal peptide (VIP) and nitric oxide 
(NO). Acetylcholine (ACh) mediates the parasympathetic vasodilation 
response to irritation. Substance P (SP) and calcitonin gene-related peptide 
(CGRP) released from nociceptive nerve endings induce vasodilation of 
blood vessels in their innervation territory. Perfusion of facial skin is 
more complex due to arteriole–venule shunts, innervated by sympathetic 
and nociceptive nerve fibres. Sympathetic vasodilators may dilate the 
shunt which shortcuts the nutritive superficial blood flow, leading to skin 
temperature changes and a loop of inflammation (by nociceptor activation), 
and an increase in inflammatory mediators. NA: noradrenaline.
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increase skin temperature and shortcut the nutritive 
superficial blood flow. In patients with chronic pain, 
increased expression of α2c-adrenoceptors on nocice-
ptors innervating these arteriole–venule shunts have 
been reported (67). Even though there is no evidence 
for disturbed alpha-adrenergic signalling in rosacea 
flushing, facial erythema can be reduced by the cuta-
neous application of an α-adrenoceptor agonist (6, 68).
TREATMENT OPTIONS
This section will focus on treatment options for trans-
ient or persistent erythema, based on our current know-
ledge of this symptom, as discussed above. Table SI1 
summarises the range of treatment options for patients 
with erythema of rosacea.
General therapeutic strategies (including those targe-
ting inflammatory perilesional erythema of papules and 
pustules) have been recently discussed in detail else-
where (2, 69–73). Firstly, both transient and persistent 
erythema are due to vasodilation. Secondly, we do not 
know to what extent the vasodilation of transient flushing 
is inflammatory. Recent publications have emphasised 
that erythema is an inflammatory skin condition and 
not just a cosmetic problem (1, 14, 16, 34). Therapeutic 
success is hindered by the fact that until recently, there 
have been no effective anti-inflammatory topicals that 
control the inflammation or vasodilation without the 
severe adverse effects that treatments such as topical 
glucocorticosteroids induce (74). Similarly, topical cal-
cineurin inhibitors, although sometimes effective, can 
also induce or aggravate rosacea (75, 76). Laser therapy 
has proven to be an effective therapeutic strategy for 
facial erythema in some cases (77), although evidence-
based information is limited (78). Anecdotally, although 
evidence-based data are lacking, adverse events of laser 
therapy, particularly post-treatment purpura, may also 
occur. In the opinion of the authors, this may be due 
to an aggravation of the inflammation present. A thera-
peutic strategy may be to combine laser therapy with an 
anti-inflammatory regimen, e.g. with modified-release 
doxycycline or other anti-inflammatory antibiotics. Ran-
domised, controlled studies to support this combination 
strategy are critically needed. 
Brimonidine 0.33% topical gel (Mirvaso®, Galderma, 
Paris, France) is a topical pharmacological treatment 
specifically developed and indicated for the persistent 
facial erythema of rosacea (79). Due to a salt policy 
enacted in the United States and European Union, the 
strength is expressed in terms of the active moiety (bri-
monidine 0.33%) rather than the salt-strength equivalent 
that was used in the clinical trials (brimonidine tartrate 
0.5%). It is, however, the same drug concentration (80). 
In phase 2 and phase 3 (including long-term) clinical 
trials, the efficacy of brimonidine 0.33% topical gel over 
vehicle has been demonstrated. In these studies, brimo-
nidine 0.33% reduced facial erythema significantly, as 
soon as 30 min after topical application. The effect was 
transient, with facial erythema reappearing after 9–12 h 
(81, 82). Adverse events reported in long-term studies 
following patients for up to 52 weeks were generally 
mild or moderate in intensity, and tachyphylaxis was not 
observed (83). A few patients experienced worsening of 
erythema shortly after application of brimonidine gel. 
It is unclear at present which patients could be at risk 
for this adverse event. 
It should be noted that antihypertensive drugs may 
also be used in the treatment of rosacea. For example, 
beta blockers, which may cause vasoconstriction of 
the cutaneous arterial blood vessels (via blocking 
the arterial β2-adrenergic receptor) are used off-label 
for the treatment of erythema (84). Calcium channel 
activation induces vasodilation by acting on vascular 
smooth muscle. The use of calcium channel blockers 
in the treatment of rosacea is not encouraged, based on 
the observation that these agents may induce or enhance 
symptoms (85), although a link could not be established 
for triggering or exacerbation of rosacea symptoms with 
calcium channel blockers in a recent study (86). In the 
same study, it was shown that beta blockers such as 
atenolol and bisoprolol were associated with slightly 
reduced risks during drug use (86). 
Most approved agents and off-label medical therapies 
targeting inflammatory lesions (Table SI1) are known 
to have additional benefits in terms of perilesional ery-
thema (34). The recent update of the Cochrane review 
of interventions for rosacea concluded that there was 
high-quality evidence to support the effectiveness of the 
following approved agents in this setting, i.e. azelaic 
acid, doxycycline, ivermectin and brimonidine (78). 
To conclude, management strategies in rosacea 
should be based on individual patient symptoms; the 
psychological and psychosocial impact of the disease 
should also be considered (11, 87). It is important to 
educate patients, to identify and avoid possible trigger 
factors and convey the importance of everyday skin 
care to maintain the integrity of the skin barrier (while 
avoiding agents that could exacerbate symptoms) (11). 
CONCLUSIONS AND FUTURE DIRECTIONS
Transient or persistent diffuse vascular erythema is 
the most common symptom of rosacea and has been a 
considerable unmet need in many patients with rosa-
cea (10). Although the precise causes of the different 
subtypes of erythema in patients with rosacea and their 
pathophysiologies are still a topic of investigation and 
can vary between patients, the most consistent findings 
in rosacea patients are vascular abnormality and facial 
erythema (88). The welcome addition of brimonidine 
tartrate to the armamentarium of treatments for rosacea 
can offer relief from the symptoms of facial erythema 
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for patients with rosacea. Recent long-term studies 
have shown brimonidine 0.33% topical gel to be safe, 
well tolerated and effective for the treatment of trans-
ient as well as persistent erythema in rosacea patients. 
Future studies will need to demonstrate additional 
efficacy for facial (not papule or pustule-associated) 
erythema, which can be observed in all subtypes of 
rosacea, including OR. Due to the purely symptomatic 
nature of this effective therapy, research is still requi-
red to develop a pathophysiology-based therapy for 
erythema and inflammation in rosacea.
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